Want to see VTVT full AI Analyst Report?
Top Page
vTv Therapeutics
(NASDAQ:VTVT)
Select Model
Select Model
Rating:53Neutral
Price Target:
$31.00
▲(0.88% Upside)
Action:Reiterated
Date:08/07/26
The score is driven primarily by mixed financials: a strong, low-leverage balance sheet offsets ongoing losses and negative cash flow. Technical signals are moderately supportive, but the very high P/E provides limited valuation support.
Positive Factors
Debt-free balance sheet
Zero debt and a substantial equity base give vTv financial flexibility to fund research and absorb setbacks without immediate leverage pressure. This strengthens resilience while the company advances clinical programs and seeks external funding or partnerships.
Negative Factors
Persistent cash burn
Negative operating and free cash flow means the business is not self-funding its research activities. Continued development will likely require cash reserves, equity issuance, or partnerships, creating financing dependence until programs produce sustainable inflows.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero debt and a substantial equity base give vTv financial flexibility to fund research and absorb setbacks without immediate leverage pressure. This strengthens resilience while the company advances clinical programs and seeks external funding or partnerships.
Read all positive factors
vTv Therapeutics (VTVT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$123.80M
Dividend YieldN/A
Average Volume (3M)5.07K
Price to Earnings (P/E)―
Beta (1Y)0.47
Revenue Growth216600.00%
EPS Growth75.57%
CountryUS
Employees26
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)0.16
Shares Outstanding3,953,928
10 Day Avg. Volume5,801
30 Day Avg. Volume5,072
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)5.23
Price to Sales (P/S)0.00
P/FCF Ratio-13.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$58.20Price Target Upside89.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.55
Revenue Forecast (FY)$37.36M
vTv Therapeutics Business Overview & Revenue Model
Company Description
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, vTv Therapeutics primarily seeks to generate value and potential revenue through the development and advancement of its drug candidates rather than through steady recurring sales from an established p...
vTv Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
64
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.84M | 0.00 | 1.02M | 0.00 | 2.02M | 4.00M |
| Gross Profit | 36.84M | 0.00 | 1.02M | 0.00 | 2.02M | 4.00M |
| EBITDA | -6.39M | -31.06M | -22.52M | -25.86M | -24.77M | -17.52M |
| Net Income | -4.76M | -26.97M | -18.46M | -20.25M | -19.16M | -12.99M |
Balance Sheet | ||||||
| Total Assets | 87.59M | 89.90M | 38.27M | 11.02M | 33.24M | 25.47M |
| Cash, Cash Equivalents and Short-Term Investments | 86.64M | 88.93M | 36.75M | 9.45M | 12.13M | 13.41M |
| Total Debt | 0.00 | 0.00 | 169.00K | 529.00K | 716.00K | 932.00K |
| Total Liabilities | 8.96M | 25.46M | 23.96M | 29.57M | 27.40M | 10.25M |
| Stockholders Equity | 78.63M | 64.44M | 12.20M | -24.68M | -10.74M | -9.74M |
Cash Flow | ||||||
| Free Cash Flow | -16.76M | -25.25M | -25.31M | -19.08M | -15.27M | -19.31M |
| Operating Cash Flow | -16.76M | -25.25M | -25.31M | -19.08M | -15.25M | -19.31M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 4.40M | -21.00K | 0.00 |
| Financing Cash Flow | 77.48M | 77.44M | 52.61M | 12.00M | 13.98M | 26.98M |
vTv Therapeutics Technical Analysis
Negative
30.73
Price Trends
33.13
Negative
34.21
Negative
33.91
Negative
Market Momentum
-0.41
Positive
44.17
Neutral
19.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTVT, the sentiment is Negative. The current price of 30.73 is below the 20-day moving average (MA) of 32.29, below the 50-day MA of 33.13, and below the 200-day MA of 33.91, indicating a bearish trend. The MACD of -0.41 indicates Positive momentum. The RSI at 44.17 is Neutral, neither overbought nor oversold. The STOCH value of 19.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTVT.
vTv Therapeutics Risk Analysis
vTv Therapeutics disclosed 19 risk factors in its most recent earnings report. vTv Therapeutics reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
vTv Therapeutics Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | $123.80M | -284.64 | -6.27% | ― | 216600.00% | 75.57% | |
51 Neutral | $257.16M | -8.12 | -48.20% | ― | 8906.15% | 41.48% | |
50 Neutral | $81.88M | -6.46 | -30.19% | ― | ― | 32.81% | |
48 Neutral | $304.90M | -3.66 | -58.00% | ― | ― | ― | |
47 Neutral | $68.11M | -0.74 | -53.22% | ― | ― | 55.84% | |
44 Neutral | $53.96M | -1.18 | 214.97% | ― | -31.12% | -35.10% |
* General Sector Average
VTVT
vTv Therapeutics
31.48
16.26
106.77%
ATHE
Alterity Therapeutics
4.56
-0.39
-7.84%
IFRX
InflaRx
2.18
1.30
147.17%
CLNN
Clene
4.09
-0.39
-8.71%
PLRX
Pliant Therapeutics
1.15
-0.32
-21.77%
ADAG
Adagene
4.05
2.09
106.63%
vTv Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
vTv Therapeutics Shareholders Approve Directors, Question Executive Pay
Neutral
Jun 29, 2026
At its Annual Meeting of Stockholders held on June 26, 2026, vTv Therapeutics shareholders elected all nominated directors to serve until the 2027 annual meeting, reinforcing continuity in the company’s board leadership. The vote results sho...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.